Abstract: Approximately 90% of uveal melanomas develop in the choroid, with the remainder arising in the ciliary body or the iris. The treatment of uveal melanoma is aimed at conserving the eye and useful vision, and, if possible, preventing metastatic disease. Enucleation is now reserved for tumors that are large and/or involve the optic disc, having largely been replaced by various forms of radiotherapy (plaque brachytherapy, proton beam or stereotactic radiotherapy) and laser therapy. Whereas iridectomy and iridocyclectomy are widely performed, transscleral exoresection of choroidal tumors is performed only in a few centers because it requires special skills and hypotensive anesthesia. Transretinal endoresection using vitrectomy equipment is easier but controversial because of concerns about tumor seeding. Long-term postoperative surveillance is necessary to identify and treat local tumor recurrence and any other complications, such as radiation-induced morbidity, and to provide counseling to the patient. Factors predicting metastasis include older age, large tumor size, ciliary body involvement, extraocular spread, epithelioid cytomorphology, chromosome 3 loss, chromosome 8q gain, class 2 gene expression profile, loss of BRCA1-associated protein-1 (BAP1), and the presence of inflammation. Prognostication is enhanced by multivariable analysis combining clinical, histologic, and genetic factors, also taking the patient's age and sex into account. As there is a lack of options for treating metastases, much research is focused on identifying potential therapeutic targets.
U veal melanoma (UM) is more common in individuals with fair skin and light-colored eyes and has an incidence of approximately 6 per million per year in whites and 0.38 per million per year in Asians.
1 Other predisposing factors include benign lesions such as nevus, melanocytosis, and melanocytoma, although UM may occasionally develop as part of the recently identified BAP1 tumor predisposition syndrome, which is the result of a germline mutation in the BRCA1-associated protein-1 (BAP1) gene.
2 Presentation of sporadic UM before adulthood is rare and the mean age at diagnosis is 60 years in whites, 3 whereas it seems to occur at a younger age in Asians: a recent study of 171 Chinese cases reported a mean age at diagnosis of 49 years 4 and an Indian study of 103 patients found the median age to be 46 years. 5 A study in 16 Japanese patients reported a mean age at diagnosis of 55 years. 6 Both sexes are affected in equal numbers. 7, 8 Approximately 90% of all uveal melanomas involve the choroid, with the remainder arising in the ciliary body or iris. Without timely treatment, patients are threatened with visual handicap, pain, and facial disfigurement. Despite successful eradication of the ocular tumor, up to 50% of patients develop metastatic disease, which typically involves the liver and is usually fatal within a year of onset of symptoms, as no effective therapies targeting metastases yet exist.
9 Adjuvant therapies and screening do not seem to provide a significant survival benefit and the apparent benefit may be due to the earlier detection of metastases in an asymptomatic phase (ie, "lead-time bias").
10,11
Ocular treatment is aimed at conserving the eye and useful vision, and, if possible, preventing metastatic disease.
12 Therapeutic modalities include enucleation and various forms of radiotherapy, tumor resection, and laser therapy. Ocular and systemic outcomes depend on a wide variety of factors. Prognostication (see below) is important for individualizing long-term surveillance and psychological support.
The aim of this paper is to describe the current methods of treatment and prognostication.
TREATMENT
An important question is whether ocular treatment of uveal melanoma can prevent metastatic disease. When local treatment with irradiation became available and enucleation of the eye was no longer the only possible treatment, discussions arose as to whether irradiation might be associated with higher mortality. A large study, the Collaborative Ocular Melanoma Study (COMS), was conducted in the United States to compare survival after enucleation with that after iodine-125 plaque radiotherapy in medium-sized tumors. The COMS reported no significant survival difference between these 2 types of treatment.
13 Although this conclusion is probably correct, the study lacked statistical power because many patients developed metastases so soon after treatment that systemic disease must already have been present at the time of ocular treatment.
14 High-risk factors for metastasis are more common in older patients, possibly suggesting that early treatment of the primary tumor prolongs survival in some patients with uveal melanoma
Radiotherapy
Most patients are treated with radiotherapy, which can consist of (a) brachytherapy, (b) proton beam radiotherapy, or (c) stereotactic radiotherapy.
Brachytherapy is delivered with a saucer-shaped plaque, which in most centers contains iodine-125 or ruthenium-106. These emit gamma and beta radiation, respectively. Ruthenium plaques are suitable for tumors not exceeding 5 mm in thickness, but the application of thermotherapy may help to reduce the thickness in some cases. 16 Gamma rays have a longer range, making it possible to treat thicker tumors, albeit with a greater risk of collateral damage to the optic disc, macula, and lens. The applicator is sutured to the sclera adjacent to the tumor and removed after delivering a dose of at least 85 Gy to the tumor apex. Conventionally, the size of the plaque is selected so that it physically overlaps the entire tumor margin by at least 2 mm. Damato 17 has, however, developed methods for accurately positioning a ruthenium plaque eccentrically, with its posterior edge aligned with the posterior tumor margin (Figs. 1A, B) . Special measures, such as intraoperative ultrasonography or transillumination, are performed to ensure that the plaque is well positioned in relation to the tumor. Notched plaques are used for juxtapapillary tumors, accepting the high likelihood of optic neuropathy and visual loss. Successful treatment of iris melanoma has been reported with customized plaques. 18, 19 Several authors have reported that local tumor control and visual outcome after brachytherapy are best with small tumors not extending close to the optic disc and fovea. [20] [21] [22] [23] [24] However, many tumors do not fit into this category. The American Brachytherapy Society has recently presented guidelines for plaque brachytherapy of choroidal melanoma.
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Proton beam radiotherapy exploits the phenomenon whereby charged particles release ionizing radiation when they stop traveling (Bragg peak). This enables high, uniform doses of radiation to be delivered to the tumor with relative sparing of superficial tissues. The treatment involves (a) insertion of 4 or 5 tantalum markers at known distances from the tumor margins, from each other, and from the limbus; (b) simulation, with preparation of treatment plans, a face mask, and dental bite, to A B ensure correct positioning of the patient's head; and (c) delivery of a dose of approximately 56 Gy, delivered over 4 consecutive days. Conventionally, a safety margin of around 2 mm is prescribed, unless the tumor extends close to the optic disc, when a narrower safety margin is used, with the aim of avoiding optic neuropathy. With ciliary body tumors and diffuse melanoma, wider safety margins are prescribed to reduce the risk of local tumor recurrence. Conventionally, proton beam radiotherapy is delivered with the eyelids retracted out of the radiation field; however, with superior tumors, damage to the upper eyelid can occur, with keratinization of the palpebral conjunctiva and painful keratitis. To avoid these complications, Damato and associates 26 have developed a protocol for transpalpebral proton beam radiotherapy. Methods for proton beam radiotherapy of iris melanoma have been developed, as a means of avoiding the need for iridectomy. [27] [28] [29] As with brachytherapy, the best results after proton beam radiotherapy are achieved with small tumors not extending close to the optic disc and fovea. [30] [31] [32] [33] [34] With stereotactic radiotherapy, radiation is directed at the tumor from multiple directions, either concurrently with the Leksell gamma knife, or sequentially with the linear accelerator (LINAC) or cyberknife. This provides high doses of radiation to the tumor while sparing surrounding tissues. Outcomes have been reported by several authors.
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Laser Therapy
Laser photocoagulation, with brief shots of high-energy light, is associated with a high recurrence rate. This treatment has been superseded by transpupillary thermotherapy (TTT), whereby a 3-mm beam of infrared laser is delivered to the tumor to heat it by a few degrees for about 1 minute. 38, 39 As tumor cells in the sclera are not always killed, 40 this treatment should preferably be accompanied by a radioactive plaque. Combined treatment of large tumors with proton beam therapy and TTT led to a reduced number of enucleations. 41 However, a recent retrospective study from Leiden, where TTT was developed, did not report differences in outcome between plaque treatment with and without TTT.
42 Some tumors respond to photodynamic therapy using agents such as verteporfin.
Excision
Exoresection of a tumor in the ciliary body or the choroid involves en bloc tumor excision using a lamellar scleral flap to close the scleral opening. 44 Excision of large tumors is usually performed with systemic hypotensive anesthesia to reduce hemorrhage. The surgery is demanding so that few authors have reported outcomes. [45] [46] [47] [48] Iridectomy is performed through a limbal incision, if possible with iridoplasty to reduce photophobia. Conventionally, iridocyclectomy is performed in an anteroposterior direction with mydriasis; however, Damato and associates 49 have found it easier to conserve the iris if the tumor is excised in a posteroanterior direction, constricting the pupil before starting the resection. Adjunctive radiotherapy is usually administered to prevent local tumor recurrence while reducing the need for wide safety margins.
With endoresection, the tumor is removed with a vitreous cutter (Figs. 2A, B) . 44 The procedure involves the following steps: (a) total 3-port vitrectomy; (b) piecemeal tumor removal with a 25-gauge vitreous cutter, either through a retinotomy over the tumor apex or by making a circumferential incision near the ora and folding back the retina; (c) endolaser photocoagulation to destroy any residual tumor; (d) flattening of the retina, usually with heavy liquid, and laser retinopexy; (e) fluid-silicone exchange; and (f) cryotherapy to the sclerotomies. Long-term outcomes have been reported after primary endoresection.
50-52 Some authors are concerned about seeding, preferring to perform this operation only after neoadjuvant proton beam or stereotactic radiotherapy.
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The silicone oil is removed after 12 weeks, with lensectomy and intraocular lens implantation.
Enucleation is required in about 20-40% of patients. Determining factors for this operation include large tumor size, extensive involvement of the ciliary body or iris, and proximity to the optic disc. 55 This operation is performed in a standard fashion, inserting an orbital implant. Outcomes after nonporous and porous implants are similar. 56, 57 Evisceration is contraindicated. Exenteration is required only exceptionally if there is extensive orbital invasion.
Treatment Selection
The choice of treatment varies greatly between centers according to the therapeutic modalities available, the surgeon's A B expertise and experience, along with the patient's needs and concerns. 58 Randomized clinical trials comparing different treatments are rare because few centers have a choice of therapy and also because the uncertainty required for randomization is lacking in most patients.
In Liverpool, where a wide range of therapeutic modalities is available, the first choice of treatment for choroidal and ciliary body melanoma is ruthenium plaque radiotherapy to avoid collateral damage to eyelids, canaliculi, and other anterior structures. Such brachytherapy is avoided if there is an excessive risk of local tumor recurrence because of large tumor size and/or difficult tumor location. In such cases, proton beam radiotherapy is preferred. If the risk of radiation-induced optic neuropathy is high because the tumor extends close to optic disc, then endoresection is considered, but only if the patient understands and accepts the controversial nature of this procedure. If radiotherapy is associated with a high risk of toxic tumor syndrome (see below), then exoresection may be preferred. Primary transpupillary thermotherapy or photodynamic therapy is administered only if the tumor is very small and if radiotherapy is likely to cause visual loss.
Treatment is selected in a consensual manner, after discussing with the patient all the advantages and disadvantages of each therapeutic option. B.D. follows this approach irrespective of the patient's ethnicity but has noticed that patients he has treated from Asia have been more highly motivated to retain the eye than British patients.
Tumor Harvesting
In patients treated with radiotherapy or laser therapy, the tumor can be sampled transsclerally or transretinally with a 25-gauge or 27-gauge needle or vitreous cutter using the transscleral or transretinal approach for anterior and posterior tumors, respectively.
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After local resection or enucleation, a tumor sample is removed before the remainder of the specimen is placed in fixative.
Ocular Surveillance
Patients are usually reviewed 1-3 days after surgery, then after 3-6 weeks, then every 3-6 months for a few years, and eventually once every year or two. The objectives are to detect and treat any side effects or complications and to provide counseling.
Local tumor recurrence can be central, marginal, or distant, with respect to the original tumor. It is assessed and treated using the same principles as the primary tumor. Orbital recurrence after enucleation may be treated by removal of all visible tumors with adjunctive orbital radiotherapy, resorting to exenteration only if these measures fail to achieve local tumor control.
Radiation-induced vasculopathy within the tumor can cause exudation, ischemia, production of angiogenic factors, retinal detachment, and in severe cases, neovascular glaucoma (ie, "toxic tumor syndrome"). 60 If mild, this can be treated by intravitreal injection of steroids or antiangiogenic agents. 61 More severe disease requires tumor ablation by laser therapy or excision.
12,62 Visual loss from macular edema is usually irreversible but may be prevented by prophylactic antiangiogenic injections administered every 4 months.
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Radiation-induced optic neuropathy is essentially untreatable. If recent, this condition indicates a need for monthly review for several months, as it predisposes to neovascular complications such as vitreous hemorrhage and glaucoma.
Neovascular glaucoma after radiotherapy can be prevented by antiangiogenic agents. 61 Once it develops, this complication may respond to intracameral injection of antiangiogenic agents or by surgical removal of the toxic mass. 60 Secondary glaucoma caused by diffuse tumor spread along the angle may be treatable by drainage surgery but only if the tumor has been sterilized by radiotherapy. 64, 65 Cataract is treated in the usual fashion.
Systemic Surveillance
Systemic surveillance is aimed at detecting metastatic disease before this becomes symptomatic. This is in the hope of prolonging life by systemic therapy or focal ablation or excision, ideally as part of a clinical trial. Surveillance also has psychological benefit, reassuring patients that any metastatic disease is unlikely to develop in the next 6-9 months. 66 There is no consensus as to which patients should undergo surveillance for metastasis, how often examinations should be performed, and for how long.
In many centers, abdominal magnetic resonance imaging (MRI) is the preferred method of screening because of its high sensitivity and specificity. 67 Unlike computerized tomography (CT) and positron-emission tomography (PET) it does not expose the patient to cumulative radiation.
68 Ultrasonography (US) is less expensive and preferred in some centers if performed by an experienced examiner and if the patient is lean. Liver function tests are insensitive. Chest radiography is only rarely useful as a surveillance measure because lung metastases usually develop after metastases become manifest in the liver.
PROgNOSTiCATiON Scope
The objectives of survival prognostication are (a) to avoid unnecessary systemic investigations in patients with a good prognosis and (b) to identify patients at high risk of metastatic disease so that they can prepare themselves and their family for any eventuality, and also so that they can receive systemic adjuvant therapy (ideally as part of a clinical trial) and/or treatment for overt metastases as early as possible. Although a good prognosis would be expected to enhance patients' well-being, such a benefit does not necessarily occur.
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Risk Factors
The risk of metastatic disease is estimated according to demographic, anatomic, histologic, and genetic predictors.
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With choroidal and ciliary body tumors, anatomic predictors include largest basal tumor diameter, tumor thickness, ciliary body involvement, and extraocular spread. [72] [73] [74] We analyzed the relation between several of these markers and prognosis in the Leiden cohort, which includes data on a series of 631 patients with uveal melanoma who underwent primary enucleation between 1983 and 2014. The mean follow-up time of the cohort was 7.4 years. In keeping with the existing literature, up to 50% of our patients eventually died from metastasis approximately 20 years after enucleation (Fig. 3A) . No sex difference in survival was found (Fig. 3B ), but patients under 60 showed a better survival than those over 60 (Fig. 3C) (P < 0.001). Largest tumor diameter and tumor thickness were analyzed according to the COMS and American Joint Committee on Cancer (AJCC) classifications. [75] [76] [77] Patient survival worsens with increasing COMS and AJCC stage (both P < 0.001) and is most unfavorable when tumors are "large" according to COMS (Fig. 3D) or AJCC Stage III (Fig. 3E) . The AJCC staging system classifies tumors based on the tumor size, localization of the tumor in the ciliary body, and extraocular growth of the tumor. Although the COMS classification only utilizes tumor size, ciliary body involvement and extraocular growth of the tumor are also strongly associated with poor survival when evaluated separately (both P < 0.001) (Figs. 4A, B) . The AJCC staging system therefore provides more precise prognostication, which is especially useful when a prognostic biopsy is not performed. This is the case in many centers.
With iris melanoma, the chances of metastasis are greater in patients with angle involvement and raised intraocular pressure.
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This is probably because these features are associated with diffuse tumor growth.
In choroidal melanoma, histologic predictors include presence of epithelioid melanoma cells, closed loops as vascular mimicry patterns, 79 presence of macrophages and lymphocytes, increased HLA expression, high microvascular density, high mitotic count, and loss of nuclear immunostaining for BAP1 protein. [80] [81] [82] [83] [84] [85] [86] We analyzed the effect of cell type and mitotic count on survival in the Leiden cohort: the prognosis of tumors of the mixed and epithelioid cell type was comparable and worse than the outcome of cases with a spindle-cell type (P < 0.001) (Fig.  4C) . When using 5 mitoses per 40 high-power fields as a cut-off, we observed that tumors with a mitotic count equal to or higher than 5 had a more unfavorable prognosis (P < 0.001, Fig. 4D ).
Genetic predictors for metastasis include chromosome 3 deletion (partial or total), the prognostically unfavorable class 2 gene expression profile, BAP1 loss, chromosome 8q gain, chromosome 1p loss, and chromosome 9q loss. [87] [88] [89] [90] [91] [92] The presence of an SF3B1 (splicing factor 3b subunit 1) mutation is associated with late-onset metastases. A class 1 gene expression profile, chromosome 6p gain, and the presence of an EIF1AX (eukaryotic translation initiation factor 1A, X-linked) mutation are associated with a good prognosis. [93] [94] [95] [96] [97] As new therapeutic modalities are related to immune responses, it is important to combine prognostication with information on the potential development of immune responses. In uveal melanoma, loss of one chromosome 3 is associated with the presence of an increased number of intratumoral macrophages and T cells. 85, 98 When metastases resemble their primary tumor immunologically, it may be that those also show an association between increased numbers of intratumoral T cells and macrophages and monosomy 3. Such metastases may then be the ones that may be responsive to immunotherapy with immune checkpoint inhibitors.
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Laboratory Techniques
A wide variety of methods are being used for genetic analysis of uveal melanoma.
94,100-102 A comprehensive review of these methods is beyond the scope of this article and thus only a few are mentioned here. When one performs a biopsy, it is important to know that a tumor may be heterogeneous so that a specific marker may be expressed only in 1 area of the tumor.
103 Fluorescence in-situ hybridization (FISH) provides limited information, failing to detect all chromosome aberrations.
104 Multiplex ligationdependent probe amplification (MLPA) provides information on chromosomes 1, 3, 6, and 8 and is therefore more informative than FISH with a few probes. 105 In addition, MLPA can be performed successfully on biopsy samples obtained after radiotherapy.
106 Several types of chromosome testing are less successful on samples taken after secondary enucleation. 107 Gene expression profiling analyzes the expression patterns of mRNA, categorizing tumors as class 1 and class 2, 108, 109 and is also successful with very small specimens; however, metastatic death has been reported in some patients with class 1 tumors so that class 1 tumors are now subcategorized into class 1A and class 1B based on the differential expression of a marker, PRAME. 110 The 5-year metastatic risk of class 1A tumors is 2%, whereas this number is 21% for class 1B PRAME-positive cases.
91 Next-generation sequencing is a new and effective approach to determine the presence of chromosome aberrations and mutations.
94 Next-generation sequencing of more than 70 uveal melanoma at the University of California, San Francisco shows good correlations with accepted metastasis predictors, but survival studies are still in progress (The Cancer Genome Atlas project, unpublished data, 2017; Afshar, Bastian, Damato, et al, unpublished data, 2017) . 
Statistical Methods
Until recently, survival prognostication was mostly based on anatomic factors. The COMS categorization has generally been superseded by the tumor, node, metastasis (TNM) staging system of the AJCC. 77, 111 These methods provide only an approximate prognosis based on size and are mostly relevant to groups of patients.
In a growing number of centers, prognostication is based on genetic tumor typing, using the methods described above. We analyzed the relation between chromosome 3 and 8q status and prognosis in the Leiden cohort (Fig. 5) . The chromosome 3 status was determined in 311 patients, whereas the chromosome 8q status was known in 273 tumors. We confirmed the association of monosomy 3 and chromosome 8q gain with poor survival (both P < 0.001; Figs. 5A, B) . Combining information on chromosome 3 and 8q status results in additional stratification of the prognosis.
Monosomy 3 tumors with additional chromosome 8q gain have a worse prognosis than those without a gain of chromosome 8q (P < 0.001; Fig. 5C ). No significant effect on survival was observed in the Leiden cohort when chromosome 8q status was evaluated in tumors without monosomy 3 (Fig. 5D) .
However, such genetic analyses only determine whether the uveal melanoma is lethal. In 2007, Damato and colleagues 104 in Liverpool improved survival prognostication by combining information on the genetic tumor type with tumor diameter and melanoma cell type. Since then, others have confirmed the value of combining genetic studies with other survival predictors, such as tumor size.
112 Adding information on the tumor's chromosome status to the categorization of tumor size, location, and extraocular extension as used by the AJCC improves the prognostication value of both. 113 We analyzed the value of combining these prognostic parameters in the Leiden enucleation cohort (Figs. 5E, F) . In monosomy 3 tumors, AJCC stage III tumors have the worst prognosis, whereas the outcome is comparable for stage I and stage II cases (P < 0.001; Fig. 5E ). No significant additional stratification of survival was observed in cases without monosomy 3 (Fig. 5F ). 113 Damato and associates 114, 115 have developed and validated the Liverpool Uveal Melanoma Prognosticator Online (LUMPO), which analyzes anatomic, histologic, and/or genetic predictors, also taking into account the patient's age and sex (Fig. 6 ). This online system allows one to obtain the patient's individual prognostic chances (www.ocularmelanomaonline.org). Thanks to these advances, prognostication is now accurate enough to be relevant to individual patients.
CONCLuSiONS
The treatment of uveal melanoma has improved so that it is often possible to conserve the eye. The visual outcome depends on tumor size and proximity to the optic nerve and fovea. It is not known whether ocular treatment ever prolongs survival and if so in whom. Uveal melanoma are less responsive to systemic therapy than cutaneous melanoma, and therapies need to be developed to treat metastases effectively. There is, nevertheless, much scope for estimating survival probability. The accuracy of such prognostication has improved thanks to genetic tumor typing, especially when multivariable analysis is performed combining anatomic, histologic, and genetic factors and also considering age and sex. 
